Engineering Immune Organoids to Study Pediatric Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 25
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Eligibility criteria
Qualifiers
Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
Brain tumors
Renal tumors
Neuroblastoma
Disqualifiers
Any histology not mentioned in the inclusion criteria
Adult patient or parents/guardians incapable/incapable of giving its/their consent
Patients deprived of their liberty by a judicial or administrative decision
Trial design
Treatments tested in this trial
- Skin biopsy
- Fresh tumor sample
- Blood sample
- Healthy tissue from the tumor
- Spinal cerebrospinal fluid (SCF)
Treatment groups
108 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov